Compare Eli Lilly And Co (LLY) vs State Street PDR S&P Retail ETF (XRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs State Street PDR S&P Retail ETF — how do they compare? Eli Lilly And Co trades at $1,177.57 (market cap $1.04T), while State Street PDR S&P Retail ETF trades at $84.12 (market cap $389.66M). The key difference: Eli Lilly And Co is far larger — about 2669× State Street PDR S&P Retail ETF's market cap, and Eli Lilly And Co pays a 0.59% dividend while State Street PDR S&P Retail ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and State Street PDR S&P Retail ETF for 45 Days on average.
| LLY | XRT | |
|---|---|---|
Market Cap | $1.04T | $389.66M |
Volume | 3,064,878 | 4,275,820 |
Sector | Health | Broad Market / Factor |
52-Week High | $1.28K | $92.35 |
52-Week Low | $799.57 | $77.28 |
Typical Hold Time | 93 Days | 45 Days |
Enterprise Value | $1.09T | — |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
XRT trades at $84.09, up 1.42% with a bullish technical signal despite mixed moving averages and oscillators. The ETF faces headwinds from higher interest rates and inflation impacting consumer sentiment, with Seeking Alpha noting underperformance against IVV YTD. Recent retail sales data shows volatility, with August rebounding 1.2% after July's unexpected 0.6% decline. The holiday season projection of $1 trillion in sales provides potential upside catalyst.
The retail ETF's outlook remains challenged by macroeconomic pressures, though selective consumer spending and potential Fed easing could support recovery. Key risks include persistent inflation and interest rate sensitivity, while technical support at $81-83 levels provides near-term stability. Analyst sentiment appears cautious given the unsupportive macro environment heading into 2027.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About State Street PDR S&P Retail ETF
XRT is an equal-weighted ETF that tracks the U.S. retail sector. It provides diversified exposure to apparel, automotive, and online retailers, including well-known names like Amazon, Target, and Costco.
Read more on XRT →
